Table 3.

Comparison of taniborbactam plasma and ELF exposures achieved in humans receiving 0.5 g every 8 h as 4 h infusion versus infected mice receiving taniborbactam in combination with cefepime human-simulated regimen subcutaneously

Matrix/regimen	Species	%fT>MIC for an MIC (mg/L) of:							fAUC0–24 (mg·h/L)	fC max (mg/L)	ELF:plasma penetration
		2	4	8	16	32	64	128
Plasma
	Human	99	83	53	0	0	0	0	205.2	15.0
ȃTaniborbactam 1.56% HSR	Mouse	0	0	0	0	0	0	0	3.2	0.2
ȃTaniborbactam 12.5% HSR	Mouse	0	0	0	0	0	0	0	22.1	1.6
ȃTaniborbactam 100% HSR	Mouse	98	93	65	5	0	0	0	229.9	18.1
ELF
ȃTaniborbactam 1.56% HSR	Mouse	0	0	0	0	0	0	0	3.5	0.2	1.11
ȃTaniborbactam 12.5% HSR	Mouse	0	0	0	0	0	0	0	21.0	1.5	0.95
ȃTaniborbactam 100% HSR	Mouse	100	89	51	0	0	0	0	195.2	15.1	0.85

HSR, human-simulated regimen.